Form 4: NEONC Technologies Grants 200,000 Restricted Shares to Chief Clinical Officer Under Incentive Plan

NEONC Technologies Holdings, Inc. has granted 200,000 shares of restricted common stock to its Chief Clinical Officer, Yousha Neman-Ebrahim, as part of its 2023 Equity Incentive Plan.

Summary

• Yousha Neman-Ebrahim, Chief Clinical Officer of NEONC Technologies Holdings, Inc. (NTHI), was granted 200,000 shares of restricted common stock on June 5, 2025.
• The grant was made pursuant to the Issuer's 2023 Equity Incentive Plan and detailed in a Restricted Stock Award Agreement.
• Of the total shares, 66,000 shares are set to vest seven months from the grant date.
• An additional 67,000 shares will vest in 29 equal monthly installments following the initial vesting period.
• The remaining 67,000 shares are performance-based, with vesting contingent upon the achievement of specific performance metrics.
• The performance-based shares represent a target number and are subject to adjustment based on actual metric achievement.

Sentiment

Score: 7

Explanation: The grant of restricted stock to a key officer, especially with a performance-based component, is generally viewed positively as it aligns management incentives with shareholder interests and indicates a commitment to future performance.

Positives

• The grant of restricted stock to the Chief Clinical Officer aligns management's interests with those of shareholders, incentivizing long-term performance.
• The inclusion of performance-based vesting for a significant portion of the grant (approximately 33.5%) ties executive compensation directly to the company's strategic and operational achievements.
• The use of an existing 2023 Equity Incentive Plan demonstrates a structured approach to executive compensation and retention.

Risks

• The vesting of approximately 67,000 shares is predicated on the achievement of certain performance metrics, meaning these shares may not fully vest if the targets are not met.
• The actual number of performance-based shares deliverable is a target number and subject to adjustment, introducing uncertainty regarding the final equity compensation.

Future Outlook

The performance-based component of the equity grant suggests that the company has defined strategic and operational goals for its Chief Clinical Officer, which are expected to contribute to future company performance and value creation.

Management Comments

• Yousha Neman-Ebrahim, Chief Clinical Officer, was granted 200,000 shares of restricted common stock under the Issuer's 2023 Equity Incentive Plan.

Industry Context

Equity incentive plans, particularly those with performance-based vesting, are a common practice in the biotechnology and pharmaceutical industries to attract, retain, and motivate key executives. Such grants aim to align the interests of management with long-term shareholder value creation, especially in sectors with long development cycles and significant R&D investments.

Comparison to Industry Standards

• The structure of this equity grant, combining time-based and performance-based vesting, is consistent with common executive compensation practices observed across the biotechnology and healthcare sectors.
• Companies like Moderna (MRNA) or BioNTech (BNTX) frequently utilize similar equity incentive structures to motivate their R&D and clinical leadership, tying compensation to milestones such as clinical trial progression, regulatory approvals, or commercialization targets.
• The proportion of performance-based shares (one-third of the total grant) is within the typical range for executive grants, often seen in companies aiming to balance retention with performance accountability.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of management's interests with long-term company performance and value creation.
• Employees: The equity grant to a key executive may signal stability and a commitment to retaining top talent, potentially boosting morale.

Next Steps

• Vesting of 66,000 shares seven months from June 5, 2025.
• Commencement of 29 equal monthly vesting installments for 67,000 shares after the initial seven-month period.
• Achievement and evaluation of specific performance metrics for the vesting of the remaining 67,000 performance-based shares.

Key Dates

Keywords

NEONC Technologies Holdings, NTHI, Restricted Stock, Equity Incentive Plan, Executive Compensation, Insider Transaction, Form 4, Performance-Based Vesting, Chief Clinical Officer, Stock Grant